Paramètres des cookies

Ce site web utilise des cookies à des fins d'optimisation et d'analyse statistique et pour afficher des annonces personnalisées. Pour plus d'informations, veuillez svp. consulter notre déclaration de confidentialité sur la protection de données personnelles.

curasan AG

euro adhoc: curasan AG
other
Curasan extends dental product range for US distribution
FDA grants 510(k) approval for Cerasorb® M Dental and Cerasorb® Perio

27.07.2005 – 17:09

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
27.07.2005
curasan AG - specialists in regenerative medicine - today received
510(k) approval by the FDA for Cerasorb® M Dental and Cerasorb®
Perio.
Cerasorb® is a synthetic bone regeneration material that is fully
resorbed by the body and replaced with autogenous bone. Cerasorb® M
Dental is a second-generation product, featuring even faster
resorption and bone replacement. It is used in regions exposed to
lower loads and complements the classic Cerasorb®.
In addition, the company has developed a product by the name of
Cerasorb® Perio, which is designed specifically for bone defects
caused by periodontitis. Thus, curasan has taken a major step forward
in terms of developing indication-specific Cerasorb® products.
"In autumn 2004, we introduced our own sales organisation for the US
dental market. Cerasorb® M Dental and Cerasorb® Perio underline our
ambitions as a leader within the field of state-of-the-art bone
regeneration. Our target group will see the extension of our
Cerasorb® portfolio as evidence of our commitment to the marketplace
and will support our sales activities in this area," said curasan’s
CEO H.D. Rössler.
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an
exchange-listed company, is a leading innovator within the growth
market of bone and tissue regeneration. The company has developed a
comprehensive product range centred around its synthetic bone
regeneration material Cerasorb®, for use in soft and hard tissue.
curasan AG's main goal is to occupy a leading position as a global
specialist in Regenerative Medicine. For further information, please
visit curasan’s corporate website at: www.curasan.de
end of announcement                               euro adhoc 27.07.2005 16:32:26

Further inquiry note:

Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 465, eMail: ir@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Börsen: Frankfurter Wertpapierbörse
Berliner Wertpapierbörse
Hamburger Wertpapierbörse
Baden-Württembergische Wertpapierbörse
Börse Düsseldorf
Niedersächsische Börse zu Hannover
Bayerische Börse
Bremer Wertpapierbörse (BWB)

Plus de actualités: curasan AG
Plus de actualités: curasan AG